葡萄糖稳态
胰高血糖素样肽-1
受体
胰高血糖素受体
肽
肠促胰岛素
胰高血糖素
兴奋剂
内科学
内分泌学
生物
化学
生物化学
糖尿病
胰岛素
医学
2型糖尿病
胰岛素抵抗
作者
Fenghui Zhao,Qingtong Zhou,Zhaotong Cong,Kaini Hang,Xinyu Zou,Chao Zhang,Yan Chen,Antao Dai,Anyi Liang,Qianqian Ming,Mu Wang,Li-Nan Chen,Peiyu Xu,Rulve Chang,Wenbo Feng,Tian Xia,Yan Zhang,Beili Wu,Dehua Yang,Lihua Zhao,H. Eric Xu,Ming‐Wei Wang
标识
DOI:10.1038/s41467-022-28683-0
摘要
Glucose homeostasis, regulated by glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) is critical to human health. Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity. To elucidate the molecular mechanisms by which tirzepatide, a GIPR/GLP-1R dual agonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, manifest their multiplexed pharmacological actions over monoagonists such as semaglutide, we determine cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1R as well as peptide 20-bound GIPR, GLP-1R and GCGR. The structures reveal both common and unique features for the dual and triple agonism by illustrating key interactions of clinical relevance at the near-atomic level. Retention of glucagon function is required to achieve such an advantage over GLP-1 monotherapy. Our findings provide valuable insights into the structural basis of functional versatility of tirzepatide and peptide 20.
科研通智能强力驱动
Strongly Powered by AbleSci AI